New Jersey A 3793: Clarifies that product approval from U.S. Food and Drug Administration is not required for drug manufacturer to file registration statement, and specifies timeframe by which DOH must review registration statements.

Status: Substituted by S2024 (as of 2016-10-20)

State: New Jersey · Session: 217 · Bill: A 3793

Subjects: DRUG ABUSE, REGULATORY

Sponsors: Benson, Daniel R., Conaway, Herb, Eustace, Tim, McKnight, Angela V., Mukherji, Raj, Peterson, Erik, O'Scanlon, Declan J., Pinkin, Nancy J.

View New Jersey A 3793 on LegisTrack → — full text, sponsors, votes, campaign finance, and cross-state matches.